Binder Information
| Binder General Information | Top | |||
|---|---|---|---|---|
| Binder ID |
BVL86Y
|
|||
| Binder Name |
Salmeterol xinafoate
|
|||
| Synonyms |
Salmetedur; Arial; Serevent diskus; GR 33343X xinafoate; Salmeterol 1-hydroxy-2-naphthoate; Salmeterol (xinafoate); GR 33343 G; SALMETEROLO; MFCD00897708; NCGC00094372-03; Asmerole; Betamican; Dilamax; Inaspir; Ultrabeta; Beglan; DSSTox_CID_25798; DSSTox_RID_81137; DSSTox_GSID_45798; Serevent Inhaler and Disks; Salmeterolxinafoate; SMR000875207; Salmeterol xinafoate [USAN:USP]; Serevent (TN); SCHEMBL18070; MLS001332577; MLS001332578; LIPO-202; CHEMBL1082607; DTXSID1045798; C36H45NO7; CTK8B9015; Salmeterol xinafoate (JAN/USP); HMS2232I16; HMS3263K22; HMS3676P13; HMS3749I03; HMS3885J19; BCP04778; Tox21_111270; Tox21_501100; ANW-61823; s4296; AKOS016004957; Tox21_111270_1; CCG-270203; CS-1527; GR-33343 G; KS-1140; LP01100; NCGC00015938-05; NCGC00094372-01; NCGC00094372-02; NCGC00094372-04; NCGC00261785-01; HY-17453; BCP0726000003; AB0020656; DB-057527; EU-0101100; FT-0642283; V1621; Salmeterol xinafoate, >=98% (HPLC), solid; D00687; W-5199; SR-01000597359; Q-201697; SR-01000597359-1; Q27264747; Salmeterol xinafoate, European Pharmacopoeia (EP) Reference Standard; Salmeterol xinafoate, United States Pharmacopeia (USP) Reference Standard
Click to Show/Hide
|
|||
| Binder Type |
Small molecular drug
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C36H45NO7
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O.C1=CC=C2C(=C1)C=CC(=C2O)C(=O)O
|
|||
| InChI |
1S/C25H37NO4.C11H8O3/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21;12-10-8-4-2-1-3-7(8)5-6-9(10)11(13)14/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2;1-6,12H,(H,13,14)
|
|||
| InChIKey |
XTZNCVSCVHTPAI-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:9012
|
|||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.